Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-Ffluorothymidine (F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses-0

<p><b>Copyright information:</b></p><p>Taken from "Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-[F]fluorothymidine (F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses"</p><p>http://www.biomedcentral.com/1471-2385/7/3</p><p>BMC Nuclear Medicine 2007;7():3-3.</p><p>Published online 3 Jul 2007</p><p>PMCID:PMC1931583.</p><p></p>�24 h), between day 1 and 7 (1–7 d) and later than one week (>1 wk) after FLT injection. Lines link all values for an individual patient over time. On Figure F (same data as Figure E) the mean +/- standard deviation for albumin is plotted over time. Dotted horizontal lines illustrate the upper and lower normal limits (reference range) for each test

Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-Ffluorothymidine (F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses-4

<p><b>Copyright information:</b></p><p>Taken from "Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-[F]fluorothymidine (F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses"</p><p>http://www.biomedcentral.com/1471-2385/7/3</p><p>BMC Nuclear Medicine 2007;7():3-3.</p><p>Published online 3 Jul 2007</p><p>PMCID:PMC1931583.</p><p></p>�24 h), between day 1 and 7 (1–7 d) and later than one week (>1 wk) after FLT injection. Lines link all values for an individual patient over time. On Figure F (same data as Figure E) the mean +/- standard deviation for albumin is plotted over time. Dotted horizontal lines illustrate the upper and lower normal limits (reference range) for each test

Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-Ffluorothymidine (F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses-5

<p><b>Copyright information:</b></p><p>Taken from "Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-[F]fluorothymidine (F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses"</p><p>http://www.biomedcentral.com/1471-2385/7/3</p><p>BMC Nuclear Medicine 2007;7():3-3.</p><p>Published online 3 Jul 2007</p><p>PMCID:PMC1931583.</p><p></p>1 and 7 (1–7 d) and later than one week (>1 wk) after FLT injection. Lines link all values for an individual patient over time. On Figures A & C the means +/- standard deviations for red blood cells (A) and hematocrit (C) are plotted over time. Dotted horizontal lines illustrate the upper and lower normal limits (reference range) for each test

Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-Ffluorothymidine (F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses-2

<p><b>Copyright information:</b></p><p>Taken from "Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-[F]fluorothymidine (F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses"</p><p>http://www.biomedcentral.com/1471-2385/7/3</p><p>BMC Nuclear Medicine 2007;7():3-3.</p><p>Published online 3 Jul 2007</p><p>PMCID:PMC1931583.</p><p></p

Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-Ffluorothymidine (F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses-1

<p><b>Copyright information:</b></p><p>Taken from "Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-[F]fluorothymidine (F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses"</p><p>http://www.biomedcentral.com/1471-2385/7/3</p><p>BMC Nuclear Medicine 2007;7():3-3.</p><p>Published online 3 Jul 2007</p><p>PMCID:PMC1931583.</p><p></p>1 and 7 (1–7 d) and later than one week (>1 wk) after FLT injection. Lines link all values for an individual patient over time. On Figures A & C the means +/- standard deviations for red blood cells (A) and hematocrit (C) are plotted over time. Dotted horizontal lines illustrate the upper and lower normal limits (reference range) for each test

Additional file 2: Figure S2. of The dog prostate cancer (DPC-1) model: a reliable tool for molecular imaging of prostate tumors and metastases

PSMA expression in lymph node metastases. Sacro-iliac LNs of varying size harvested at necropsy (top left), with largest ones being often necrotic (lower left). IHC with 17G1 confirmed PSMA expression in DPC-1 cells forming LN metastases (top right) and remaining debris in necrotic ones (lower right) (×40)